The Patent Finder

Oxford Biotherapeutics Ltd.

8 patents currently held · Updated Nov 21, 2026
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.

Recorded under 2 name spellings.

2
Ending by 2030
Feb 2028
Next term end

When these terms end

Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045

Fee deadlines

Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
  • 1 fee due Dec 13, 2026
    The maintenance fee for Crtam Antibodies and Methods of Treating Cancer (US 11,673,963) comes due Dec 13, 2026. Unpaid by Jun 14, 2027, it lapses early.
  • 1 fee due May 10, 2027
    The maintenance fee for Antibodies Specific to Cadherin-17 (US 9,181,339) comes due May 10, 2027. Unpaid by Nov 10, 2027, it lapses early.
  • 1 fee due Jun 1, 2027
    The maintenance fee for Protein (US 9,200,055) comes due Jun 1, 2027. Unpaid by Dec 1, 2027, it lapses early.
  • 1 fee due Jul 5, 2027
    The maintenance fee for ANTI-ROR1 Antibodies and Methods of Use for Treatment of Cancer (US 9,228,023) comes due Jul 5, 2027. Unpaid by Jan 5, 2028, it lapses early.

Which patents, and when each one lapses · Pro

Recent changes

  • 2 of the patents on this record were granted since Aug 23, 2026

Patents held now

Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.

Showing 1 to 8 of 8

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 8,084,034Proteins
In force
 · High confidence
In forceHigh confidence
US 9,200,055Protein
In force
 · High confidence
In forceHigh confidence
US 9,181,339Antibodies Specific to Cadherin-17
In force
 · High confidence
In forceHigh confidence
US 9,228,023ANTI-ROR1 Antibodies and Methods of Use for Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 10,081,682Conjugated Antibodies Against LY75 for the Treatment of Cancer
In force
 · High confidence
In forceHigh confidence
US 12,799,221Crtam Antibodies and Methods of Treating Cancer
In force
 · Medium confidence
In forceMedium confidence
US 11,673,963Crtam Antibodies and Methods of Treating Cancer
In force
 · High confidence
In forceHigh confidence
US 12,799,199Antibodies and Methods of Use
In force
 · High confidence
In forceHigh confidence
Also on record, not counted in the 8: 1 patent in force now held by others · 11 lapsed for an unpaid fee. List them

Sources and methods

Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.

Published applications

US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.

3 pending · 10 abandoned · 9 no status recorded

List them

The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited